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Kingella kingae is the leading pathogen of osteoarticular infection (OAI) in <4-year-21 
old children in different countries where improved culture methods and nucleic acid 22 
amplification assays are routinely employed (1). The oropharynx is recognized as the portal of 23 
entry for K. kingae, which can penetrate the bloodstream and invade distant organs, facilitated 24 
by several virulence factors such as a recently described polysaccharide capsule (2). On an 25 
international collection of 150 invasive and carriage isolates from 10 countries, Porsch et al. 26 
(2) have described four capsule types using a multiplex polymerase chain reaction (PCR) 27 
approach. Over 95% of invasive isolates in the collection were type ‘a’ or type ‘b’, while 28 
capsule type ‘c’ and type ‘d’ were more commonly observed among carriage isolates (2, 3). 29 
This distribution was described on K. kingae isolates; however K. kingae is a fastidious 30 
bacterium and whether the strains harboring a capsule type ‘a’ or ‘b’ can be more easily 31 
cultivated from clinical samples is unknown. Such difference may lead to biased 32 
epidemiological results. Moreover, among this collection, 30 invasive isolates were from 33 
France, mainly isolated from 2010 to 2013 (n=24/30, range 1972-2013). To our knowledge, 34 
no more recent data are available yet, and whether the epidemiology has changed remains to 35 
be determined. 36 
We aimed to describe the K. kingae capsule serotypes using a multiplex PCR protocol, as 37 
recently described (4), on a fraction of our collection of osteoarticular samples, which were 38 
positive with the K. kingae specific real-time PCR, used as routine in our laboratory (5). 39 
From July 2013 to April 2018, we found 115 K. kingae-positive osteoarticular samples from 40 
105 patients (1 to 3 per patients). Samples origins were: joint fluid (95/105; 90.5%), synovial 41 
biopsy (8/105; 7.6%), bone abscess (1/105; 0.9%), and sub-cutaneous collection (1/105; 42 
0.9%). Samples origins were: joint fluid (95/105; 90.5%), synovial biopsy (8/105; 7.6%), 43 
bone abscess (1/105; 0.9%), and sub-cutaneous collection (1/105; 0.9%).Capsular PCR 44 
allowed identifying unambiguously a capsule type in all of these 115 samples (Figure 1).  45 
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Among the 105 patients, the PCR results showed 71 (67.6%) capsules ‘a’, 33 (31.4%) 46 
capsules ‘b’, 1 (0.9%) capsule ‘c’, and no capsule ‘d’. When multiple samples were available 47 
for one patient, the results were identical for each sample. There was no significant variation 48 
between distribution of capsules ‘a’ and ‘b’ along the study period or by age or whether the 49 
culture was positive or negative (Table 1).  50 
In a large collection of K. kingae-positive osteoarticular samples in France, we 51 
demonstrated that our capsular PCR is able to identify the capsular serotypes of invasive K. 52 
kingae in skeletal system specimens. Knowing that rtxA/B and cpn60 PCRs cannot 53 
discriminate K. kingae from K. negevensis and Simonsiella muelleri, respectively, it may be 54 
suggested that adding the capsular PCR to the molecular diagnosis may increase its specificity 55 
(4). We observed that 99% of K. kingae OAI involved a strain harboring a capsule type ‘a’ or 56 
‘b’, which is similar to that observed in the Israeli and the international collections of invasive 57 
isolates (2, 3). Our results strengthen the hypothesis that the type ‘a’ and type ‘b’ capsules 58 
may have enhanced pathogenic properties. Polysaccharide capsules are a common target for 59 
development of vaccine, such as pneumococcal vaccine; the implication of capsules ‘a’ and 60 
‘b’ in K. kingae invasive infections could be of high interest for the development of a K. 61 
kingae vaccine. On the other hand, very few data on the distribution of capsule serotypes 62 
among carriage isolates are available yet. In a recent study it was described that types ‘a’ and 63 
‘b’ were predominant in a small population of healthy children carrying K. kingae in France 64 
(4). A better characterization of the distribution of K. kingae capsular serotypes among 65 
healthy carriers would lead to better understand the role played by the capsule in the potential 66 
of the organism to cause invasive infection. 67 
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Legend to Figure 88 
Figure 1. Gel electrophoresis of the Kingella kingae multiplex capsular PCR in 89 
osteoarticular samples. The molecular weight is related to the capsule serotype: ‘a’, ‘b’, ‘c’ 90 
and ‘d’ types are identified from the highest to the lowest molecular weight, respectively (lane 91 
4). Capsule type ‘a’ was identified in 4 samples (lanes 1, 6, 7 and 8), capsule type ‘b’ was 92 
identified in 2 samples (lanes 3 and 5), and capsule type ‘c’ was identified in 1 sample (lane 93 
2). Lane 9, sterile water; Lane 10, DNA ladder. 94 
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Capsule ͚a͛  
;n=7ϭͿ 
Capsule ͚ď͛  
;n=33Ϳ 
Capsule ͚Đ͛  
;n=ϭͿ 
Year     
ϮϬϭϯ Ϯϰ ϭϵ ;ϳϵ.ϮͿ ϱ ;ϮϬ.ϴͿ Ϭ 
ϮϬϭϰ ϭϯ ϴ ;ϲϭ.ϱͿ ϱ ;ϯϴ.ϱͿ Ϭ 
ϮϬϭϱ Ϭ - - - 
ϮϬϭϲ ϭϵ ϭϬ ;ϱϮ.ϲͿ ϵ ;ϰϳ.ϰͿ Ϭ 
ϮϬϭϳ ϯϵ Ϯϲ ;ϲϲ.ϳͿ ϭϮ ;ϯϬ.ϴͿ ϭ ;Ϯ.ϲͿ 
ϮϬϭϴ ϭϬ ϴ ;ϴϬ.ϬͿ Ϯ ;ϮϬ.ϬͿ Ϭ 
Age     
<ϭ year ϯϬ ϮϬ ;ϲϲ.ϳͿ ϭϬ ;ϯϯ.ϯͿ Ϭ 
ϭ year ϲϬ ϰϭ ;ϲϴ.ϯͿ ϭϴ ;ϯϬ.ϬͿ  ϭ ;ϭ.ϳͿ 
Ϯ years ϭϮ ϳ ;ϱϴ.ϯͿ ϱ ;ϰϭ.ϳͿ Ϭ 
ϯ years Ϯ Ϯ ;ϭϬϬ.ϬͿ Ϭ Ϭ 
ϰ years ϭ ϭ ;ϭϬϬ.ϬͿ Ϭ Ϭ 
Culture      
Positive ϭϭ ϳ ;ϲϯ.ϲͿ ϰ ;ϯϯ.ϰͿ Ϭ 
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